SCHEMBL18153367

SCHEMBL18153367

Cc1ccc(Nc2cc(N3CCCCC3)nc(N3CCN(C(=O)OC(C)(C)C)CC3)n2)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GALR2 O43603 6/20 0.55
GALR1 P47211 4/20 0.55
MAPT P10636 3/20 0.52
APAF1 O14727 2/20 0.52
GAA P10253 2/20 0.52
PPP1CA P62136 1/20 0.52
SENP8 Q96LD8 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
SENP6 Q9GZR1 1/20 0.52
GBA1 P04062 5/20 0.50
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ACHE P22303 1/20 0.45
BPTF Q12830 1/20 0.44
GPR119 Q8TDV5 3/20 0.43
LMNA P02545 1/20 0.43
CKS1B P61024 1/20 0.43
SKP1 P63208 1/20 0.43
SKP2 Q13309 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18162424 0.99 GALR2 (0.55) GALR2GALR1MAPTAPAF1GAA
SCHEMBL18153343 0.91 LMNA (0.57) GALR2GALR1MAPTGAAGBA1
SCHEMBL18063521 0.87 MAPT (0.58) GALR2GALR1MAPTSMN1; SMN2ACHE
SCHEMBL18063528 0.86 ACHE (0.48) GALR2GALR1MAPTSMN1; SMN2ACHE
SCHEMBL18153351 0.86 ACHE (0.52) GALR2GALR1MAPTAPAF1GAA
SCHEMBL18153425 0.86 GALR2 (0.53) GALR2GALR1MAPTSMN1; SMN2BPTF
SCHEMBL18162439 0.85 ACHE (0.47) GALR2GALR1MAPTHTTSMN1; SMN2
SCHEMBL18153311 0.85 MAPT (0.58) GALR2GALR1MAPTAPAF1GAA
SCHEMBL18153403 0.84 GALR2 (0.48) GALR2GALR1MAPTSMN1; SMN2ACHE
SCHEMBL18162512 0.83 ACHE (0.46) GALR2GALR1MAPTSMN1; SMN2ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3283472-B1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS UNIV INDIANA RES & TECH CORP (US) 2021-04-14 EP disclosed
US-10273228-B2 Hepatitis B viral assembly effectors INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2019-04-30 US disclosed
US-20180099952-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-04-12 US disclosed
US-20180099952-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-04-12 US disclosed
EP-3283472-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS Indiana University Research&Technology Corporation (US) 2018-02-21 EP disclosed
WO-2016168619-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2016-10-20 WO disclosed
WO-2016168619-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2016-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180099952-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS HAVCR2, MAVS, HCCS GALR2 3809/4885GALR1 3419/4885MAPT 4486/4885
US-10273228-B2 Hepatitis B viral assembly effectors HAVCR2, MAVS, HCCS GALR2 3809/4885GALR1 3419/4885MAPT 4486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.